Biotech entity
Every one of those 3 sits in a single category, fda-approval. BPC-157 is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Across an 8-day span, the pace is roughly 2.6 stories per week. Their average consequence score of 5.7 runs below the beat's 5.9 for that window.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, fda-approval. BPC-157 is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Across an 8-day span, the pace is roughly 2.6 stories per week. Their average consequence score of 5.7 runs below the beat's 5.9 for that window. Source depth averages 2.3 original sources per story, versus 2.4 across the same-window beat baseline. TB-500 appears in 3 tracked Biotech stories published from July 27, 2026 through August 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 62 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TB-500. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
A divided FDA panel backed three unapproved peptides for pharmacy compounding despite agency warnings of insufficient safety data. The vote raises concerns about political influence and the erosion of evidence-based standards in biopharmaceutical regulation.
Source: nbcdfw.com · nbcnewyork.com
TB-500 is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
